Newly Diagnosed ALL or T-cell Study AALL0434

Newly Diagnosed ALL or T-cell Study AALL0434

Share this:

Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Leukemia.

PROTOCOL ID

COG # AALL0434

PROTOCOL DESCRIPTION

This study is for patients with newly diagnosed T-cell lymphoblastic leukemia (T-ALL) or T-lineage lymphoblastic lymphoma (T-NHL) stage II-IV.

ELIGIBILITY CRITERIA

  • Patients with T-ALL must be enrolled on AALL08B1 before treatment on AALL0434 begins.
  • Patients with T-NHL are not eligible for AALL08B1 and can enroll directly on to AALL0434.
  • Patients must be greater than 1 year and less than 31 years of age.

Primary Investigator(s)

Mandy Atkinson, M.D.

Contact Information

Wendy McCarty, Clinical Research Coordinator
Office: 540-981-7376
wpmccarty@carilionclinic.org